drug discovery
The companies will leverage Absci's AI-enabled Integrated Drug Creation platform and the pharma giant's oncology research and development expertise.
The company will use the funds to grow its drug-discovery pipeline and clinical AI stack.
Mati Gil, CEO of AION Labs, describes how its new startup OMEC.AI came to fruition and what it aims to accomplish for drug discovery and development.
Also, Standigm has partnered with Merck Korea for AI drug discovery research.
The study will accumulate objective lifestyle data from around 2,000 participants.
They aim to bring down the period and costs for new drug development.
The multiyear agreement will focus on speeding clinical trials and drug development in oncology and nonalcoholic steatohepatitis.
Also: Rupa Health raised $20 million for its lab test platform, and CancerIQ scooped up $14 million in Series B funding.
Automata aims to scale capacities for life scientists.
The company said the latest round brings its total raise to $47 million.